Novel Pancreatic Cancer Drug Combination Shows Tumor Disappearance in Trials

A combination of daraxonrasib and chemotherapy achieved complete tumor disappearance in 8% of metastatic pancreatic cancer patients in an early clinical trial, offering new hope.

Novel Pancreatic Cancer Drug Combination Shows Tumor Disappearance in Trials
Photo-illustration WireIsrael: AI Generated

A novel combination therapy involving the investigational drug daraxonrasib and standard chemotherapy has yielded promising results in an early-stage clinical trial involving patients with metastatic pancreatic cancer. Researchers reported that visible tumors completely vanished in five out of 61 patients, representing approximately 8 percent of participants who achieved a complete response. The findings were presented at the international EORTC-NCI-AACR conference in Barcelona by Dr. Wonarki Park, an oncologist at the Memorial Sloan Kettering Cancer Center in New York.

Clinical Findings and Survival Rates

During the Phase 1/2 trial, designated as RMC-GI-102, about 61 percent of participants experienced significant tumor shrinkage or complete disappearance, while roughly 77 percent were alive one year after treatment. Overall, disease control—defined as tumors shrinking, disappearing, or remaining stable without progression—was achieved in 90.2 percent of participants. The median progression-free survival reached 12.8 months, significantly higher than the five to six months typically observed with conventional chemotherapy regimens in metastatic pancreatic cancer. Furthermore, the median duration of response among responding patients stood at 11.1 months.

Participants in the trial received daily 200-milligram oral doses of daraxonrasib alongside intravenous gemcitabine and nab-paclitaxel chemotherapy. All enrolled individuals suffered from metastatic pancreatic cancer and had not previously received systemic therapy for their advanced disease. Researchers noted that while complete radiological responses are encouraging, they do not necessarily indicate the total eradication of all cancerous cells in the body or guarantee a permanent cure.

Mechanism and Development

Pancreatic cancer remains one of the most aggressive malignancies with low long-term survival rates, largely due to late diagnoses after the disease has spread. The therapeutic potential of daraxonrasib stems from its ability to target the RAS protein, which regulates cellular division and is mutated in over 90 percent of pancreatic cancer cases. For decades, inhibiting this protein proved exceptionally difficult. Daraxonrasib works by suppressing RAS signaling, acting to block the molecular driver of tumor growth.

In August, the United States Food and Drug Administration granted approval for daraxonrasib as a single agent for previously treated metastatic pancreatic cancer, based on a Phase 3 trial showing a median overall survival of 13.2 months compared to 6.7 months with standard chemotherapy. The current trial explores its efficacy earlier in the disease progression when combined with first-line chemotherapy.

Safety Profile and Access Challenges

Adverse events associated with the combination therapy included skin rashes, diarrhea, fatigue, and decreased blood cell counts. Approximately 5 percent of patients discontinued daraxonrasib due to drug-related side effects. Rare but serious risks documented in official safety information include pulmonary toxicity, non-infectious pneumonia, and gastrointestinal perforation.

In Israel, daraxonrasib is not currently included in the public health basket. Its monthly cost in the United States is estimated at approximately 40,000 US dollars, translating to roughly 120,000 shekels. While some Israeli patients have received the medication free of charge through compassionate use programs, regulatory approvals in the United States may lead to the closure of these programs. Due to administrative timelines, public funding consideration cannot occur before January 2028.

Investigators emphasize that because the trial was an early-stage study without a control group receiving chemotherapy alone, definitive claims regarding superiority cannot yet be made. A large-scale international Phase 3 trial, named RASolute 303, is currently underway to definitively establish whether daraxonrasib combined with chemotherapy extends overall survival compared to standard treatments.

Related News